Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
Lists
Only you see this
Abstract
To our knowledge, these findings from an exploratory analysis represent the first randomized data on continuous versus fixed-duration immunotherapy in previously treated advanced NSCLC and suggest that continuing nivolumab beyond 1 year improves outcomes.
BibTeX
@article{waterhouse2020continuous,
author = {David Waterhouse and Edward B. Garon and Jason C. Chandler and Michael McCleod and Maen Hussein and Robert M. Jotte and Leora Horn and Davey B. Daniel and George P. Keogh and Ben Creelan and Lawrence H. Einhorn and Justin Baker and Samer S. Kasbari and Petros Nikolinakos and Sunil Babu and Félix Couture and Natasha B. Leighl and Craig H. Reynolds and George R. Blumenschein and Vijay Gunuganti and Ang Li and Nivedita Aanur and David R. Spigel},
title = {{Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153}},
journal = {Journal of Clinical Oncology},
year = {2020},
doi = {10.1200/jco.20.00131},
}Loading related content...